Overview

Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-centre, dose ranging study to assess efficacy, safety and pharmacokinetics of eltrombopag in thrombocytopenic subjects with chronic liver disease.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline